PTEN/MMAC1 mutations and EGFR amplification in glioblastomas

Wanguo Liu, C. David James, Lori Frederick, Benjamin E. Alderete, Robert Brian Jenkins

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Loss of heterozygosity (LOH) from chromosome 10 is a hallmark of glioblastoma, the most malignant (grade IV) form of glioma. A candidate tumor suppressor gene, PTEN/MMAC1, that may be targeted for deletion in association with chromosome 10 LOH has recently been identified. Here we have investigated 63 glioblastomas for PTEN/MMAC1 alterations and identified DNA sequence changes that would affect the encoded protein in 17 (275) tumors. Microsatellite analyses of normal-tumor DNA pairs were performed on 14 of these cases and revealed LOH at locations flanking and/or near PTEN/MMAC1 in all but 1 instance, suggesting that deletion of the remaining wild-type allele had occurred in the large majority of tumors with PTEN/MMAC1 mutations. Competitive PCR assays were developed to address the possible occurrence of PTEN/MMAC1 homozygous deletions in glioblastomas, and this analysis identified three samples having loss of both PTEN/MMAC1 alleles. EGFR amplification was determined to occur at similar frequencies among cases with or without PTEN/MMAC1 homozygous deletions or mutations, suggesting that a growth-promoting effect resulting from amplification-associated increases in epidermal growth factor receptor signaling is not necessarily dependent on the inactivation of PTEN/MMAC1.

Original languageEnglish (US)
Pages (from-to)5254-5257
Number of pages4
JournalCancer Research
Volume57
Issue number23
StatePublished - Dec 1 1997

Fingerprint

Loss of Heterozygosity
Glioblastoma
Chromosomes, Human, Pair 10
Mutation
Alleles
Neoplasms
Sequence Deletion
Tumor Suppressor Genes
Epidermal Growth Factor Receptor
Glioma
Microsatellite Repeats
Polymerase Chain Reaction
DNA
Growth
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Liu, W., James, C. D., Frederick, L., Alderete, B. E., & Jenkins, R. B. (1997). PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Research, 57(23), 5254-5257.

PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. / Liu, Wanguo; James, C. David; Frederick, Lori; Alderete, Benjamin E.; Jenkins, Robert Brian.

In: Cancer Research, Vol. 57, No. 23, 01.12.1997, p. 5254-5257.

Research output: Contribution to journalArticle

Liu, W, James, CD, Frederick, L, Alderete, BE & Jenkins, RB 1997, 'PTEN/MMAC1 mutations and EGFR amplification in glioblastomas', Cancer Research, vol. 57, no. 23, pp. 5254-5257.
Liu W, James CD, Frederick L, Alderete BE, Jenkins RB. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Research. 1997 Dec 1;57(23):5254-5257.
Liu, Wanguo ; James, C. David ; Frederick, Lori ; Alderete, Benjamin E. ; Jenkins, Robert Brian. / PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. In: Cancer Research. 1997 ; Vol. 57, No. 23. pp. 5254-5257.
@article{8aebe10f1a4141c8962a10932ddd5971,
title = "PTEN/MMAC1 mutations and EGFR amplification in glioblastomas",
abstract = "Loss of heterozygosity (LOH) from chromosome 10 is a hallmark of glioblastoma, the most malignant (grade IV) form of glioma. A candidate tumor suppressor gene, PTEN/MMAC1, that may be targeted for deletion in association with chromosome 10 LOH has recently been identified. Here we have investigated 63 glioblastomas for PTEN/MMAC1 alterations and identified DNA sequence changes that would affect the encoded protein in 17 (275) tumors. Microsatellite analyses of normal-tumor DNA pairs were performed on 14 of these cases and revealed LOH at locations flanking and/or near PTEN/MMAC1 in all but 1 instance, suggesting that deletion of the remaining wild-type allele had occurred in the large majority of tumors with PTEN/MMAC1 mutations. Competitive PCR assays were developed to address the possible occurrence of PTEN/MMAC1 homozygous deletions in glioblastomas, and this analysis identified three samples having loss of both PTEN/MMAC1 alleles. EGFR amplification was determined to occur at similar frequencies among cases with or without PTEN/MMAC1 homozygous deletions or mutations, suggesting that a growth-promoting effect resulting from amplification-associated increases in epidermal growth factor receptor signaling is not necessarily dependent on the inactivation of PTEN/MMAC1.",
author = "Wanguo Liu and James, {C. David} and Lori Frederick and Alderete, {Benjamin E.} and Jenkins, {Robert Brian}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "57",
pages = "5254--5257",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - PTEN/MMAC1 mutations and EGFR amplification in glioblastomas

AU - Liu, Wanguo

AU - James, C. David

AU - Frederick, Lori

AU - Alderete, Benjamin E.

AU - Jenkins, Robert Brian

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Loss of heterozygosity (LOH) from chromosome 10 is a hallmark of glioblastoma, the most malignant (grade IV) form of glioma. A candidate tumor suppressor gene, PTEN/MMAC1, that may be targeted for deletion in association with chromosome 10 LOH has recently been identified. Here we have investigated 63 glioblastomas for PTEN/MMAC1 alterations and identified DNA sequence changes that would affect the encoded protein in 17 (275) tumors. Microsatellite analyses of normal-tumor DNA pairs were performed on 14 of these cases and revealed LOH at locations flanking and/or near PTEN/MMAC1 in all but 1 instance, suggesting that deletion of the remaining wild-type allele had occurred in the large majority of tumors with PTEN/MMAC1 mutations. Competitive PCR assays were developed to address the possible occurrence of PTEN/MMAC1 homozygous deletions in glioblastomas, and this analysis identified three samples having loss of both PTEN/MMAC1 alleles. EGFR amplification was determined to occur at similar frequencies among cases with or without PTEN/MMAC1 homozygous deletions or mutations, suggesting that a growth-promoting effect resulting from amplification-associated increases in epidermal growth factor receptor signaling is not necessarily dependent on the inactivation of PTEN/MMAC1.

AB - Loss of heterozygosity (LOH) from chromosome 10 is a hallmark of glioblastoma, the most malignant (grade IV) form of glioma. A candidate tumor suppressor gene, PTEN/MMAC1, that may be targeted for deletion in association with chromosome 10 LOH has recently been identified. Here we have investigated 63 glioblastomas for PTEN/MMAC1 alterations and identified DNA sequence changes that would affect the encoded protein in 17 (275) tumors. Microsatellite analyses of normal-tumor DNA pairs were performed on 14 of these cases and revealed LOH at locations flanking and/or near PTEN/MMAC1 in all but 1 instance, suggesting that deletion of the remaining wild-type allele had occurred in the large majority of tumors with PTEN/MMAC1 mutations. Competitive PCR assays were developed to address the possible occurrence of PTEN/MMAC1 homozygous deletions in glioblastomas, and this analysis identified three samples having loss of both PTEN/MMAC1 alleles. EGFR amplification was determined to occur at similar frequencies among cases with or without PTEN/MMAC1 homozygous deletions or mutations, suggesting that a growth-promoting effect resulting from amplification-associated increases in epidermal growth factor receptor signaling is not necessarily dependent on the inactivation of PTEN/MMAC1.

UR - http://www.scopus.com/inward/record.url?scp=0030724320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030724320&partnerID=8YFLogxK

M3 - Article

C2 - 9393744

AN - SCOPUS:0030724320

VL - 57

SP - 5254

EP - 5257

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -